Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the previous year, the business posted ($1.00) earnings per share. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Stock Down 3.4 %

NASDAQ ELDN opened at $3.16 on Thursday. The stock has a market cap of $189.23 million, a price-to-earnings ratio of -1.57 and a beta of 0.66. Eledon Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $5.54. The business has a fifty day moving average of $3.41 and a 200-day moving average of $3.96.

Analyst Upgrades and Downgrades

Separately, Guggenheim assumed coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).